Abstract: This invention relates, e.g., to a molecular delivery system comprising A. a substrate having a nanostructured surface region which comprises a plurality of nanostructures and, covalently attached to the substrate, multiple copies of a first member of a binding pair; and B. at least one vector nanoparticle which comprises, encapsulated therein, a molecule of interest, and on its surface, multiple copies of second member of the binding pair. Methods of using the molecular delivery system to deliver a molecule of interest to a cell are also described.

Abstract: Compositions and methods are presented in which recombinant IL-11 is PEGylated to achieve improved half-life in serum while having desirable therapeutic activity and presenting less side-effects. Most preferably, the IL-11 is an N-terminally truncated human or humanized IL-11 and has a 20 Kd or 40 Kd branched PEG moiety, Y- or comb-shaped in particular, coupled to the N-terminal amino group. Such compounds are characterized by substantially increased stability in serum and sustained biological activity while exhibiting significantly reduced plasma expansion.

Abstract: This disclosure relates to targeted protease compositions and uses related thereto. In certain embodiments, the disclosure relates to nanoparticles wherein a targeting molecule is linked to the nanoparticle and wherein a catalytic domain of a protease is linked to the nanoparticle. In certain embodiments, the targeting molecule and the catalytic domain are within a single polypeptide sequence. In certain embodiments, the targeting molecule binds a molecule more highly expressed on cancer cells then non-cancerous cells, and the nanoparticles disclosed herein are used for the treatment of cancer by further attaching an anti-cancer agent to the nanoparticle or incorporating an anticancer agent within the nanoparticle.

Abstract: The present invention relates to methods for the treatment of cancers. In particular, the invention provides methods for treatment of cancer by administering an Aurora kinase inhibitor in combination with an anti-CD30 antibody. The combined administration of the Aurora kinase inhibitor and anti-CD30 antibody can be simultaneous, separate, sequential or consecutive.

Abstract: The present invention relates to biomolecule conjugates which comprise a biomolecule wherein at least one non-natural amino acid (NNAA) is integral to the structure of the biomolecule and wherein the NNAA is a point of attachment of a linker to which a payload, particularly a cytotoxic agent, is attached. More specifically, this invention relates to conjugates of cell-binding agents and active release products comprising cytotoxic agents wherein the conjugates are produced by means of a cycloaddition reaction. Methods of production, pharmaceutical compositions and methods of use are provided.

Abstract: Provided herein are immunoconjugates comprising an anti-ROR1 antibody or an antigen-fragment fragment thereof and a drug moiety. These immunoconjugates are useful for treating ROR1 expressing cancers.

Abstract: A compound which is either A: or B: and salts and solvates thereof, as well as their conjugates with a cell-binding agent.

Abstract: The present disclosure provides compositions and methods useful for tissue engineering including a composition having chemically modified RNA (cmRNA) encapsulated in or complexed with a non-viral delivery vehicle and a biocompatible, bioresorbable scaffold and methods of using the composition to regenerate, for example, bone tissue.

Abstract: Block copolymers containing charged blocks or chemical moieties sensitive to oxidation or hydrolysis have been developed. We describe the use of such block copolymers in supramolecular structures, e.g., micelles or vesicles, and pharmaceutical compositions and in methods of preparing the supramolecular structures and pharmaceutical compositions. The invention is particularly useful for the delivery of pharmaceutical agents, e.g., nucleic acids, to cells.

Abstract: A major challenge in non-viral gene delivery remains finding a safe and effective delivery system. Colloidally stable non-viral gene vector delivery systems capable of overcoming various biological barriers, are disclosed. The gene vectors are biodegradable, non-toxic and highly tailorable for use in specific applications. The vectors include a mixture of biodegradable copolymers, such as PBAE, and biodegradable polymers conjugated with hydrophilic, neutrally charged polymer, such as PEG. The gene vectors demonstrate broad vector distribution and high transgene delivery in vivo, providing an efficient non-viral gene delivery system for localized therapeutic gene transfer. Methods of using the vectors to overcome biological barriers including mucus gel and extracellular matrix are provided. Methods of formulating the vectors are also provided.

Abstract: Described herein are cyclic peptides, nanoparticles bound with cyclic peptides, and methods for using said cyclic peptides and/or said nanoparticles bound with cyclic peptides for intraoperative nerve tissue imaging.

Abstract: A freeze-dried powder composition comprising a phospholipid and a polyethylene glycol, said polyethylene glycol having a percentage of folded polymeric chains of 40% or higher. The composition is suitable for preparing gas-filled microvesicles.

Abstract: The present invention provides a compound represented by formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof. (In the formula, each of A and Z independently represents CO, SO or SO2; each of X and Y independently represents S or O; each of R1-R4 independently represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group or a halogen group; each R5 independently represents an alkyl group, an alkenyl group, an alkynyl group or a halogen group; and n represents an integer of 0-4.) This compound is capable of specifically binding to an AMPA receptor, and shows extremely high brain uptake.

Abstract: Probes which target diffuse and fibrillar forms of amyloid beta (A?) are described. These probes demonstrate high initial brain penetration and facile clearance from non-targeted regions. The agents can be used to image amyloid quantitatively for monitoring efficacy of A?-modifying therapeutics and assist in premortem diagnosis of Alzheimer's disease (AD). Disclosed probes can bind A? aggregates of preformed A?1-42 fibrils in vitro and can be used to image fibrillar and diffuse plaques ex vivo in brain sections. Disclosed probes can be used to determine A? burden in early stages of AD. These probes can be used for multimodality imaging of A?. F-AI-187 (1 ?M) can detect A? plaques in brain sections of APP/PS1 mice. F-AI-187 (10 ?M) can detect A? plaques in the frontal lobe in a brain section of a patient with confirmed AD. Some probes can be used for fluorescence imaging of plaque.

Abstract: A sterilization system uses ultraviolet radiation and ozone to eradicate deadly pathogens to sterilize wound/incision sites. The sterilization system offers a safe sterilization method prior to or after surgery and/or closure wounds/incisions. The sterilization system has ultraviolet emitters that emit ultraviolet light in wavelengths that kill pathogens and in wavelengths that produce ozone at the sites, therefore killing/disabling several hard-to-kill pathogens. The sterilization system has surface detectors to enable ultraviolet emission only when the system is properly seated against the skin so as to protect from unwanted radiation from the ultraviolet light.

Abstract: Apparatuses are disclosed having an ultraviolet lamp and a reflector system arranged to project light emitted from the lamp to a region 2-4 feet from a floor of a room in which the apparatus is arranged. The apparatuses include a mobile carriage with wheels and one or more compartments underneath the lamp that hold operational components for the apparatus. The apparatuses are configured such that the lamp is not moveable beyond vertical planes aligned with a casing of the carriage. In some cases, a lowermost surface of the lamp is arranged at an elevation substantially level with or above an upper surface of the casing that is at least 36 inches above the floor of the room. In addition or alternatively, the carriage may include a handle exterior to its casing having an uppermost surface arranged at substantially the same level or lower than a lowermost surface of the lamp.

Abstract: A fill assembly sterilization system for a blow/fill/seal machine utilizes a closed loop circulation of sterilant containing gas. A typical sterilant is nitrogen dioxide. The closed loop includes a shroud that defines a plenum and encloses the fill system. Optionally, at least one high efficiency particulate absorption (HEPA) filter is provided in the closed loop. Sterility assurance level of 10?6 can be achieved by subjecting the fill system to the sterilizing gas for at least 20 minutes at a temperature in the range of about 18° C. to about 30° C.

Abstract: Systems and methods for sanitization of surfaces, such as hands, are provided. In general, the described techniques utilize a system including a housing having an active agent receptacle in fluid communication with at least one nozzle, and an air pump in fluid communication with the at least one nozzle. The system also includes a control module configured to control the delivery of an active agent as an aerosol spray through the at least one nozzle in a delivery dose. The delivery dose is expelled onto the surface as a thin uniform layer and dried such that the entire surface sanitization process is completed in less than or equal to 5 seconds. The active agent receptacle can be configured to receive a removable and replaceable cartridge carrying the active agent.

Abstract: [Objective] To provide a pressure-sensitive adhesive agent for skin containing a pressure-sensitive adhesive agent for skin that has favorable shape retention properties and skin-follow up properties without being adversely affected by moisture from excrement or the like even when adhered to the skin over a long period of time and yet leaves no adhesive residue after separation and a pressure-sensitive adhesive sheet for skin contains a base material and a layer of the pressure-sensitive adhesive agent for skin. [Means to Achieve Objectives] A pressure-sensitive adhesive agent for skin contains 2 to 35% by weight of a thermoplastic elastomer, 25 to 60% by weight of a hydrophilic polymer compound, 16 to 40% by weight of a softener, and 0.01 to 4.8% by weight of a physiologically active agent; and has a water absorption 3 hours after of 55 to 240% and a water absorption 24 hours after of 240 to 450%.

Abstract: A method and device for use in stress female urinary incontinence. A small, flexible adhesive patch is applied directly to the clitoris of a person suffering from stress female urinary incontinence. The adhesive is of a type sufficient to stimulate the mechanoreceptors located in the clitoris whereby to inhibit discharge from the bladder. The patch is formed of a backing sheet of an impervious material containing adhesive on one side. A release liner prevents the adhesive from drying out.

Abstract: Bioadhesives and crosslinked gels therefrom are disclosed. The bioadhesives can be applied to a vessel for occluding the vessel. The present disclosure also describes kits that comprise the various components for preparing and applying the bioadhesives. Bioadhesives of the present disclosure include: (i) a biopolymer having one or more first chemically reactive amine groups; (ii) a biocompatible crosslinker having at least two second chemically reactive groups that can chemically react with the one or more first chemically reactive amine groups of the biopolymer; and (iii) a biocompatible rheological modifier.

Abstract: The present invention relates to injectable dermal filler compositions in the form of a gel, comprising hyaluronic acid (HA), carboxymethyl cellulose (CMC) and, optionally, microparticles such as calcium hydroxyapatite (CaHAP) microparticles. The injectable dermal filler compositions have improved rheological properties while at the same time have low extrusion forces. The present invention further relates to a method for preparing such injectable dermal filler compositions and their use for cosmetic and therapeutic purposes.

Abstract: A coating for a roughened metal surface of an implantable medical device includes a poly(ethylene glycol) disposed on at least a portion of the roughened metal surface, wherein the poly(ethylene glycol) is covalently bonded directly to the roughened metal surface.

Abstract: An object is to provide a composition containing a pancreatic islet, a cell structure containing a pancreatic islet or a pancreatic islet cell, a pancreatic islet transplantation kit, a pancreatic islet transplantation treatment agent, and a hypoglycemic agent which improve at least one of glucose sensitivity or blood sugar level-reducing performance after transplantation, and to provide a composition containing a pancreatic islet, a kit containing a pancreatic islet, a pancreatic islet cell transplantation treatment agent, and a hypoglycemic agent which can improve glucose sensitivity. A composition including (A): a cell structure containing a biocompatible macromolecular block and at least one kind of cell and in which a plurality of the above-described macromolecular blocks are arranged in gaps between a plurality of the above-described cells; and (B): a pancreatic islet, and a composition containing a pancreatic islet; and a spheroid formed of at least one type of stem cell are provided.

Abstract: An implantable hydrogel precursor composition can include: a cross-linkable polymer matrix that is biocompatible; and a plurality of polymer particles in the cross-linkable polymer matrix. The cross-linkable polymer matrix can include a cross-linkable hyaluronic acid polymer that has cross-linkable functional groups. The hyaluronic acid polymer can be a methacrylated hyaluronic acid polymer. The methacrylated hyaluronic acid polymer can have a molecular weight from about 500 kDa to about 1.8 MDa. The polymer particles can include a cross-linked hyaluronic acid. The cross-linkable polymer matrix having the polymer particles has a yield stress. The cross-linkable polymer matrix having the polymer particles has shape retention at physiological temperatures. The composition can include live cells in the cross-linkable polymer matrix. The composition can include a biologically active agent in the cross-linkable polymer matrix.

Abstract: Bioactive porous bone graft implants in various forms suitable for bone tissue regeneration and/or repair, as well as methods of use, are provided. The implants are formed of bioactive glass and have an engineered porosity. The implants may take the form of a putty, foam, fibrous cluster, fibrous matrix, granular matrix, or combinations thereof and allow for enhanced clinical results as well as ease of handling.

Abstract: The present invention relates to: a porous polymer material having a porous structure over the entire polymer and having a dense porous structure in which pores are connected to each other therein. The porous polymer material is harmless to the human body as it does not use toxic organic solvents. In addition, a porous polymer material can be prepared without using any additives for forming pores and the particle size can be easily controlled, and thus a polymer material suitable for various uses can be prepared. Furthermore, the extended release of a loaded bioactive material is possible only by the dense porous structure of a polymer itself without using an additive and a surface modification method in the porous polymer material of the present invention. Therefore, the porous polymer material can be applied to a biodegradable material in various bio-fields requiring the extended release of a bioactive material.

Abstract: A method to prepare a catheter locking formulation, comprising in a first step, dissolving trimethoprim in propylene glycol at a temperature greater than room temperature, and in a final step, adding absolute ethanol at about room temperature to a solution of trimethoprim, propylene glycol, EDTA Calcium Disodium Hydrate, phosphate buffered saline, and glycerin.

Abstract: Provided herein relates to implantable devices and systems with dynamic silk coatings. In some embodiments, the dynamic silk coatings can be formed in situ or in vivo.

Abstract: A device for moving contents of a tube by acting on the exterior of the tube is provided. The device includes a housing having a top portion and a bottom portion, the top portion including a tube passageway extending along a length thereof for holding a tube therein. A roller housed within a roller chassis contacts the tube and is configured to move between a first position in which the tube is disengaged and a second position in which the tube is engaged. A second roller is rotatably coupled to an actuator for rotatably energizing the second roller and is moveable between a first position in which the tube is disengaged and a second position in which the tube is engaged. A lever is operably coupled to the housing and configured to actuate a motor to move the second roller to the second position. The first roller and the second roller are configured to compress the tube to move contents within the tube.

Abstract: Described generally herein are tissue therapy devices, which may comprise a sealant layer and a suction apparatus. The sealant layer functions so as to create a sealed enclosure between it and the surface of a patient by forming, preferably, an airtight seal around an area of tissue that requires negative pressure therapy. The tissue therapy device may comprise a suction apparatus. The suction apparatus is typically in fluid communication with the sealant layer and functions so as to reduce the amount of pressure present underneath the sealant layer. The reduced pressure is self-created by the suction apparatus. Together the sealant layer and the suction apparatus preferably create a closed reduced pressure therapy system. Preferably, the pressure under the sealant layer is reduced by expanding the volume of the enclosure space and thereby decreasing the density of the air molecules under the sealant layer.

Abstract: Systems and devices for treating a tissue site may include an interface adapted to provide a reduced pressure to a dressing. The interface may include a positive-pressure channel for delivering a positive pressure from a positive-pressure port to a positive pressure outlet. The positive-pressure channel may include a constricted portion configured to provide a pressure drop. The interface may additionally include a reduced-pressure channel adapted to deliver reduced pressure to the dressing that substantially corresponds to the pressure drop. The reduced-pressure channel may be fluidly coupled between the positive pressure channel and a side of the interface body adapted to face the dressing. Other systems and devices are disclosed.

Abstract: An incontinence aid may include a pad body. The pad body may include a liquid receiving area. The incontinence aid may further include a liquid passage connected to the pad body. The liquid passage may form a boundary about a majority of the liquid receiving area. The liquid passage may include at least one lateral opening facing the liquid receiving area.

Abstract: Systems and methods can be used improve the efficacy of tube thoracostomy. For example, this document provides devices and methods for confirming the proper placement of a chest tube within the pleural space.

Abstract: A breastshield unit for use in a device for expressing human breastmilk employing underpressure with a breastshield body and a media separation device which separates expressed milk from an underpressure source arranged in the breastshield body, the media separation device having a through-channel which connects first and second openings of the breastshield body. The through-channel has a through-opening, which is enlargeable when subjected to an underpressure from outside. The through-opening is formed by walls which, when subjected to an underpressure from outside, are movable away from each other, largely without stretching, in order to enlarge the through-opening. The breastshield unit permits media separation with minimal dead volume, and with optimized comfort for the mother.

Abstract: A cover for a percutaneous connector extending through the skin of a patient. The cover includes a structure having an inner side and an outer side. A first separable connector is mounted to the structure and disposed entirely within the structure, the first separable connector being configured to detachably engage and electrically connect with the percutaneous connector. A second separable connector is mounted to the structure and electrically connected to the first separable connector, the second separable connector being exposed at the outer side of the structure and being configured to detachably engage and electrically connect with an external device. The inner side of the structure defines a skin-engaging surface at least partially surrounding the first separable connector and the percutaneous connector, when the first separable connector is engaged with the percutaneous connector.

Abstract: An implantable anastomotic assembly, which is configured to be attached to cardiovascular tissue, includes a connection interface, a plurality of outer plates, and a plurality of connectors configured to extend between and interconnect the connection interface and the plurality of outer plates, respectively, according to various embodiments. An outer plate of the plurality of outer plates is configured to be engaged against the cardiovascular tissue before a respective connector of the plurality of connectors is interconnected between the connection interface and the outer plate of the plurality of outer plates, according to various embodiments.

Abstract: A method is provided for the transcatheter delivery of an intracorporeal device and includes establishing a device delivery pathway in a patient. The device delivery pathway extends at least from an entry point into the patient to an exit point from the patient. A method is also provided for the transcatheter retrieval of an intracorporeally implanted device and includes establishing a device delivery pathway in a patient, wherein the device delivery pathway extends at least from an entry point into the patient to an exit point from the patient. A delivery device is also provided for the transcatheter delivery of an intracorporeal device through a device delivery pathway in a patient, the delivery device comprising a catheter comprising a radial separation mechanism, or a delivery catheter and detachably coupling with an intracorporeal device.

Abstract: An extracorporeal blood treatment apparatus having a fluid system and a pump for conveying fluid in the fluid system, wherein the pump is a non-occluding pump, and a method for shutting off or reducing the speed of rotation of a non-occluding pump in a fluid system of an extracorporeal blood treatment apparatus. The apparatus and the method are characterized in that before the speed of rotation is reduced or the pump is shut off, the fluid flow into the feed line and out of the discharge line is first interrupted, and after a predetermined time interval after interruption of the fluid flow has elapsed, the speed of rotation of the pump is reduced or the pump is shut off. The time-delayed shut-off of the pump prevents a reverse flow of fluid, particularly of blood into the arterial blood line, even in the absence of occlusion. As a result of the time-delayed shut-off or reduction in the speed of rotation of the pump, however, an excess pressure is produced in the fluid system.

Abstract: An extracorporeal system for lung assist includes a system housing, which includes a blood flow inlet and a blood flow outlet and a fiber bundle housing movably positioned within the system housing. The fiber bundle housing includes a gas inlet and a gas outlet. A fiber bundle is in operative connection with the fiber bundle housing. The fiber bundle includes a plurality of hollow gas permeable fibers, wherein lumens of the plurality of hollow gas fibers are in fluid connection with the gas inlet at a first end thereof and in fluid connection with the gas outlet as a second end thereof. The system further includes an actuator to impart oscillatory motion to the fiber bundle housing and thereby to the fiber bundle.

Abstract: A system for cardiopulmonary bypass, including: a cardiopulmonary bypass reservoir configured to store a blood; a pump in fluid communication with the cardiopulmonary bypass reservoir configured to provide pressure to the system; an oxygen source including a pressure regulator configured to regulate an oxygen pressure; an oxygenator fluidly connected to the pressure regulator of the oxygen source via an sweep gas inlet, wherein the sweep gas inlet is configured to have a sub atmospheric pressure and the oxygenator is configured to oxygenate the blood; a vacuum regulator fluidly connected to the oxygenator via an sweep gas outlet, and configured to provide the sub atmospheric pressure; a flow restrictor fluidly connected to the sweep gas inlet and configured to allow for a pressure drop from the oxygen source to the oxygenator; and an arterial filter fluidly connected to a blood outlet of the oxygenator and to the cardiopulmonary bypass reservoir.

Abstract: A dialysis system is disclosed including an autoconnection mechanism. The autoconnection mechanism in an embodiment is configured such that (i) a tip protector remover is translated in a first direction towards a plurality of supply line connectors, (ii) the tip protector remover is locked to each of a plurality of supply line tip protectors connected to the plurality of supply line connectors, (iii) the tip protector remover is translated in a second direction away from the plurality of supply line connectors to remove the plurality of supply line tip protectors from the supply line connectors, the tip protector remover is translated in a third direction different from the first and second directions, and (v) solution line connectors are translated towards the supply line connectors to connect each of the solution line connectors to one of the supply line connectors.

Abstract: The invention relates to a device for separating blood into its components and a method for the same and use of such a device. The device comprises a magnetic drive device, which causes a container to rotate about its own axis, wherein the container has at least one open end and at least one inlet therein and is suspended in a magnetically floating manner.

Abstract: Systems and methods are provided for determining an estimated risk of arrhythmia during or after dialysis based on changes in serum potassium concentration of a patient and an amount of fluid removed from the patient during dialysis. The systems and methods allow for a determination of a risk that arrhythmia will occur due to the changes in potassium and fluid volume of a patient during dialysis, and for optimizing a dialysis prescription in order to minimize the risk of arrhythmia.

Abstract: The present invention relates to an injection device for injecting a pharmaceutical liquid drug containing a preservative. The injection device comprises a housing (1) supporting a cartridge (20) having an interior chamber (21) holding the pharmaceutical preservative containing liquid drug to be injected, and a needle cannula (10) having a front part (11) and a back part (12), which back part (12) is adapted to be in liquid communication with the interior chamber (21) of the cartridge (20). The injection device is further provided with a telescopic needle covering shield (30) which distally is provided with a reservoir (31) which holds a liquid containing the same preservatives as in the pharmaceutical preservative containing liquid drug contained in the interior chamber of the cartridge. The telescopic needle covering shield (30) is telescopic movable in relation to the needle cannula (10) by a first resilient member between a first position and a second position.

Abstract: Disclosed is a medical injection device (1) comprising a needle assembly (20) having a cannula (21) and a telescopic shield (30) for covering the distal tip (23) in a no use situation. The telescopic shield further carries a cleaning reservoir (40) for cleaning the needle cannula between two subsequent injections. The cleaning reservoir is provided with an opening (43) connecting to an overflow reservoir (51/55) such that the cleaning liquid contained in the cleaning reservoir can retract and expand upon temperature changes and does not enter the needle lumen instead. In one example, the overflow reservoir is formed as a channel (51).

Abstract: Methods for setting up, maintaining and operating a radiopharmaceutical infusion system, that includes a radioisotope generator, are facilitated by a computer of the system. The computer may include pre-programmed instructions and a computer interface, for interaction with a user of the system, for example, in order to track contained volumes of eluant and/or eluate, and/or to track time from completion of an elution performed by the system, and/or to calculate one or more system and/or injection parameters for quality control, and/or to perform purges of the system, and/or to facilitate diagnostic imaging.

Abstract: A treatment method that increases circulation and pluripotency of stem and progenitor cells within a patient can be used to fight off or cure various diseases for the patient such as chronic kidney disease or end-stage renal disease. An administrator of the treatment method is provided with a medicinal-administration system such as an intravenous injection system. The treatment method begins by preparing a dosage of oxygen-ozone mixture with the medicinal-administration system. The medicinal-administration system then transfuses the oxygen-ozone mixture in the patient's bloodstream so that the renal system and/or the bone marrow can be targeted by the oxygen-ozone mixture. These steps are repeated as a plurality of treatment session for the patient.

Abstract: Devices, systems and methods for controlling, regulating, altering, transforming or otherwise modulating the delivery of a substance to a delivery site. The devices, systems and methods optimize the delivery of the substance to an intended site, such as a vessel, vascular bed, organ and/or other corporeal structures, while reducing inadvertent introduction or reflux substance to other vessels, vascular beds, organs, and/or other structures, including systemic introduction.

Abstract: The invention relates to a system for administering drug to a Parkinson's disease patient comprising (a) a drug; (b) a storing bag for the drug; (c) a pump for administering the drug; (d) a pump controller for controlling the pump activity, the pump controller having access to a correlation of a first parameter tx and a second parameter At, and to the current first parameter tx, wherein the first parameter tx is correlated with a certain activity of the patient and the second parameter At is correlated with a dosage of the drug and the pump controller controls the pump activity in dependence of the first parameter tx and the correlation, and/or wherein the system comprises (e) a storing hag the drug suitable for pre-filling and long-term oxidations-free storage having a multi layer wall with the internal layer made of EVA or cyclic polyolefines and at least one further layer made of EVOH.